EP3986377A4 - Formulations parasiticides à base d'isoxazoline et procédés de traitement de blépharite - Google Patents

Formulations parasiticides à base d'isoxazoline et procédés de traitement de blépharite Download PDF

Info

Publication number
EP3986377A4
EP3986377A4 EP20826079.4A EP20826079A EP3986377A4 EP 3986377 A4 EP3986377 A4 EP 3986377A4 EP 20826079 A EP20826079 A EP 20826079A EP 3986377 A4 EP3986377 A4 EP 3986377A4
Authority
EP
European Patent Office
Prior art keywords
isoxazoline
methods
treating blepharitis
parasiticidal formulations
parasiticidal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP20826079.4A
Other languages
German (de)
English (en)
Other versions
EP3986377A1 (fr
Inventor
Bobak Robert AZAMIAN
Douglas Michael ACKERMANN
Shawn HICKOK
Joseph Vehige
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tarsus Pharmaceuticals Inc
Original Assignee
Tarsus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Tarsus Pharmaceuticals Inc filed Critical Tarsus Pharmaceuticals Inc
Publication of EP3986377A1 publication Critical patent/EP3986377A1/fr
Publication of EP3986377A4 publication Critical patent/EP3986377A4/fr
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A01AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01NPRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/72Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms
    • A01N43/80Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with nitrogen atoms and oxygen or sulfur atoms as ring hetero atoms five-membered rings with one nitrogen atom and either one oxygen atom or one sulfur atom in positions 1,2
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0048Eye, e.g. artificial tears
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K20/00Accessory food factors for animal feeding-stuffs
    • A23K20/10Organic substances
    • A23K20/105Aliphatic or alicyclic compounds
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23KFODDER
    • A23K50/00Feeding-stuffs specially adapted for particular animals
    • A23K50/40Feeding-stuffs specially adapted for particular animals for carnivorous animals, e.g. cats or dogs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12Carboxylic acids; Salts or anhydrides thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/186Quaternary ammonium compounds, e.g. benzalkonium chloride or cetrimide
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/08Solutions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00Antiparasitic agents
    • A61P33/10Anthelmintics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Polymers & Plastics (AREA)
  • Ophthalmology & Optometry (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Inorganic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Animal Husbandry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Environmental Sciences (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Dentistry (AREA)
  • Birds (AREA)
  • Agronomy & Crop Science (AREA)
  • Wood Science & Technology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
EP20826079.4A 2019-06-19 2020-06-19 Formulations parasiticides à base d'isoxazoline et procédés de traitement de blépharite Pending EP3986377A4 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962863822P 2019-06-19 2019-06-19
US202063029689P 2020-05-25 2020-05-25
PCT/US2020/038758 WO2020257663A1 (fr) 2019-06-19 2020-06-19 Formulations parasiticides à base d'isoxazoline et procédés de traitement de blépharite

Publications (2)

Publication Number Publication Date
EP3986377A1 EP3986377A1 (fr) 2022-04-27
EP3986377A4 true EP3986377A4 (fr) 2023-07-19

Family

ID=74040459

Family Applications (1)

Application Number Title Priority Date Filing Date
EP20826079.4A Pending EP3986377A4 (fr) 2019-06-19 2020-06-19 Formulations parasiticides à base d'isoxazoline et procédés de traitement de blépharite

Country Status (10)

Country Link
EP (1) EP3986377A4 (fr)
JP (2) JP2022537389A (fr)
KR (1) KR20220053550A (fr)
CN (1) CN114269324A (fr)
AU (1) AU2020295570A1 (fr)
BR (1) BR112021025701A2 (fr)
CA (1) CA3144264A1 (fr)
IL (2) IL289109B2 (fr)
MX (1) MX2021016055A (fr)
WO (1) WO2020257663A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016022066A1 (fr) 2014-08-04 2016-02-11 Jerry Tan Eye Surgery Pte Ltd Compositions pharmaceutiques pour blépharite et encroûtement des paupières liés à demodex
AU2018385766B2 (en) 2017-12-15 2022-12-01 Tarsus Pharmaceuticals, Inc. Isoxazoline parasiticide formulations and methods for treating blepharitis
WO2022156371A1 (fr) * 2021-01-22 2022-07-28 成都瑞沐生物医药科技有限公司 Support ou substance auxiliaire de préparation ophtalmique, son procédé de préparation et son application
US20220323472A1 (en) * 2021-03-30 2022-10-13 Frank Anthony SPALLITTA Anti-parasitic compounds for the treatment and prevention of viral diseases
PL4312986T3 (pl) * 2021-04-01 2025-02-17 Active Biotech Ab Preparat lakwinimodu do stosowania do oczu
WO2024168149A1 (fr) * 2023-02-10 2024-08-15 Tarsus Pharmaceuticals, Inc. Formulations parasiticides à base d'isoxazoline et méthodes de traitement de la blépharite

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006119174A1 (fr) * 2005-04-30 2006-11-09 Ocular Surface Center, P.A. Methode de traitement oculaire de demodex
WO2016022066A1 (fr) * 2014-08-04 2016-02-11 Jerry Tan Eye Surgery Pte Ltd Compositions pharmaceutiques pour blépharite et encroûtement des paupières liés à demodex
WO2019118928A1 (fr) * 2017-12-15 2019-06-20 Tarsus Pharmaceuticals, Inc. Préparations de parasiticides à base d'isoxazoline et méthodes de traitement de la blépharite

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2891460B1 (fr) * 2005-09-30 2010-07-30 Galderma Sa Utilisation d'au moins un compose de la famille des avermectines pour le traitement des pathologies ophtalmiques dues au demodex folliculorum.
US20090317503A1 (en) * 2008-06-20 2009-12-24 Ocusoft, Inc. Eyelid Preparation and Method of Use
JP5246182B2 (ja) * 2010-02-24 2013-07-24 ライオン株式会社 点眼剤、防腐剤及び防腐力向上剤
BR112012026364B1 (pt) * 2010-04-12 2018-04-10 Exosect Limited Controle de artrópodes em ambientes de animais
WO2012107533A1 (fr) * 2011-02-10 2012-08-16 Novartis Ag Dérivées d'isoxazoline pour la lutte contre des animaux nuisibles invertébrés
RU2688919C1 (ru) * 2013-12-20 2019-05-23 Интервет Интернэшнл Б.В. Изоксазолиновые композиции и их применение в провилактике или лечении паразитарных инвазий животных
JP7569781B2 (ja) * 2018-07-27 2024-10-18 アペルタ バイオサイエンシズ,エルエルシー デモデックスにより誘発される眼の異常および顔面の異常を治療するためのスピノシン配合

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006119174A1 (fr) * 2005-04-30 2006-11-09 Ocular Surface Center, P.A. Methode de traitement oculaire de demodex
WO2016022066A1 (fr) * 2014-08-04 2016-02-11 Jerry Tan Eye Surgery Pte Ltd Compositions pharmaceutiques pour blépharite et encroûtement des paupières liés à demodex
WO2019118928A1 (fr) * 2017-12-15 2019-06-20 Tarsus Pharmaceuticals, Inc. Préparations de parasiticides à base d'isoxazoline et méthodes de traitement de la blépharite

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
JOHN THOMAS: "The preservative question", OPHTHALMOLOGY MANAGEMENT -, 1 August 2012 (2012-08-01), XP093052673, Retrieved from the Internet <URL:https://www.ophthalmologymanagement.com/issues/2012/august-2012/corneal-clarity> [retrieved on 20230607] *
QUIROZ-MERCADO HUGO ET AL: "Pilot Study to Evaluate the Safety and Efficacy of TP-03 for the Treatment of Blepharitis Due to Demodex Infestation (Mars Study)", vol. 21, no. 7, 1 June 2020 (2020-06-01), pages 2984, XP093052443, Retrieved from the Internet <URL:https://iovs.arvojournals.org/article.aspx?articleid=2767821> *
See also references of WO2020257663A1 *

Also Published As

Publication number Publication date
CA3144264A1 (fr) 2020-12-24
CN114269324A (zh) 2022-04-01
IL289109A (en) 2022-02-01
IL289109B2 (en) 2025-10-01
EP3986377A1 (fr) 2022-04-27
WO2020257663A1 (fr) 2020-12-24
IL321061A (en) 2025-07-01
JP2025137609A (ja) 2025-09-19
KR20220053550A (ko) 2022-04-29
BR112021025701A2 (pt) 2022-03-03
JP2022537389A (ja) 2022-08-25
IL289109B1 (en) 2025-06-01
MX2021016055A (es) 2022-04-20
AU2020295570A1 (en) 2022-02-10

Similar Documents

Publication Publication Date Title
EP3986377A4 (fr) Formulations parasiticides à base d&#39;isoxazoline et procédés de traitement de blépharite
EP3723739A4 (fr) Préparations de parasiticides à base d&#39;isoxazoline et méthodes de traitement de la blépharite
MA45290A (fr) Procédés et compositions d&#39;agents biologiquement actifs
EP3781214A4 (fr) Compositions et procédés de traitement de l&#39;amyotrophie spinale
EP3681513A4 (fr) Agents d&#39;arni et compositions destinées à inhiber l&#39;expression d&#39;analogue de l&#39;angiopoïétine 3 (angptl3) et procédés d&#39;utilisation
EP3647311A4 (fr) Inhibiteur de protéine kinase associée à rho, composition pharmaceutique le comprenant, son procédé de préparation et son utilisation
MA49045A (fr) Compositions et procédés destinés à la distribution régulée d&#39;acide
MA42819A (fr) Procédés pour le traitement d&#39;infections virales à arenaviridae et coronaviridae
EP3458585A4 (fr) Procédés de thérapie génique pour des maladies et des affections liées à l&#39;âge
EP3377042A4 (fr) Substances et procédés de traitement de myopathies à base de titine et d&#39;autres titinopathies
MA53558A (fr) Compositions et procédés pour le traitement d&#39;infections virales
EP3545106A4 (fr) Procédés d&#39;enrichissement et de détermination de séquences nucléotidiques cibles
EP3310395A4 (fr) Régulation de la transcription à guidage arn et procédés d&#39;utilisation de celle-ci pour le traitement des lombalgies
EP3833340A4 (fr) Compositions et procédés de traitement de la presbytie
EP3452578A4 (fr) Procédés de fabrication in vitro de tissu de fundus d&#39;estomac et compositions associées à celui-ci
EP3592841A4 (fr) Procédés et compositions de traitement de cancers à l&#39;aide d&#39;acides nucléiques antisens
EP3761784A4 (fr) Nouveaux procédés d&#39;élevage et libération régulée d&#39;agents de lutte biologique
EP3740463A4 (fr) Composition d&#39;oligoéléments à sources multiples et procédés de traitement du sol à l&#39;aide de celle-ci
EP4013474A4 (fr) Injecteurs de micro-volume à guidage de dose et procédés d&#39;utilisation
EP4255405A4 (fr) Procédés et compositions pour des agents thérapeutiques à base de cannabinoïdes
EP3523281A4 (fr) Activateurs de flux autophagique et de phospholipase d et clairance d&#39;agrégats de protéines comprenant tau et traitement de protéinopathies
EP3843524A4 (fr) Composition de traitement des semences et procédé d&#39;utilisation
EP3723733A4 (fr) Méthodes et compositions pour le traitement du cancer utilisant des exosomes associés à l&#39;édition génique
EP3413904A4 (fr) Compositions à base de plantes et procédés de prévention et de traitement d&#39;infections de plantes ou d&#39;infections unguéales
EP3833533A4 (fr) Fabrication d&#39;additif non orthogonal et traitement de pièces fabriquées à partir de celui-ci

Legal Events

Date Code Title Description
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE INTERNATIONAL PUBLICATION HAS BEEN MADE

PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: REQUEST FOR EXAMINATION WAS MADE

17P Request for examination filed

Effective date: 20220107

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

DAV Request for validation of the european patent (deleted)
DAX Request for extension of the european patent (deleted)
REG Reference to a national code

Ref country code: DE

Ref legal event code: R079

Free format text: PREVIOUS MAIN CLASS: A61K0009000000

Ipc: A61K0031420000

A4 Supplementary search report drawn up and despatched

Effective date: 20230619

RIC1 Information provided on ipc code assigned before grant

Ipc: A01N 43/80 20060101ALI20230613BHEP

Ipc: A01N 25/02 20060101ALI20230613BHEP

Ipc: A23K 20/105 20160101ALI20230613BHEP

Ipc: A61K 47/14 20170101ALI20230613BHEP

Ipc: A61K 47/26 20060101ALI20230613BHEP

Ipc: A61K 47/10 20170101ALI20230613BHEP

Ipc: A61P 27/02 20060101ALI20230613BHEP

Ipc: A61K 9/00 20060101ALI20230613BHEP

Ipc: A61K 31/422 20060101ALI20230613BHEP

Ipc: A61K 31/42 20060101AFI20230613BHEP

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

17Q First examination report despatched

Effective date: 20250624